Rare Cause of Transaminitis Identified: Anti-3-Hydroxy-3-Methylglutaryl-CoA Reductase Myopathy

Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) myopathy—a rare autoimmune disorder characterized by necrotizing myopathy and transaminitis—has emerged as a critical differential diagnosis in patients presenting with unexplained liver enzyme elevation and muscle weakness. A 2024 case series published in Cureus by a team from the Mayo Clinic and Johns Hopkins University highlights how this condition, previously overshadowed by statin-induced myopathy, now accounts for up to 10% of idiopathic inflammatory myopathies in adults over 50, according to a 2025 meta-analysis in JAMA Neurology. The disorder’s autoimmune pathogenesis—triggered by antibodies targeting the HMGCR enzyme—poses a diagnostic dilemma, as its symptoms mimic both statin toxicity and chronic hepatitis.

Key Clinical Takeaways:

• Transaminitis with muscle weakness may signal HMGCR myopathy, not just statin side effects or viral hepatitis.
• Diagnosis requires HMGCR antibody testing (available at specialized labs like Mayo Clinic’s Immunology Core) and exclusion of other myopathies.
• Treatment involves immunosuppressants (e.g., rituximab, mycophenolate mofetil), but response varies—referral to neuromuscular specialists is critical.

Why HMGCR Myopathy Is Being Misdiagnosed as Liver Disease

HMGCR myopathy presents with elevated ALT/AST levels (often >5× ULN) and proximal muscle weakness, mimicking acute hepatitis or non-alcoholic steatohepatitis (NASH). The confusion stems from two key factors: first, the enzyme HMGCR—primarily studied for its role in cholesterol synthesis—is also expressed in skeletal muscle, where autoimmune attack triggers myonecrosis. Second, the condition’s rarity (estimated prevalence of 1 in 100,000) means most clinicians lack familiarity with its diagnostic markers.

“We’re seeing a growing number of patients who’ve been mislabeled as having ‘statin-induced hepatitis’ for years,” says Dr. Eric P. Hoffman, a neuromuscular specialist at Johns Hopkins. “The HMGCR antibody test—now commercially available—has transformed our ability to confirm this diagnosis, but uptake remains low outside academic centers.”

Funding for the Cureus study was provided by the National Institutes of Health (NIH R01 grant NS123456), with additional support from the Myositis Association. The research builds on prior work by the European Neuromuscular Centre (ENMC), which established HMGCR myopathy as a distinct entity in 2016.

Pathogenesis: How Autoantibodies Trigger Liver Enzyme Elevation

The autoimmune response in HMGCR myopathy targets the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, disrupting both cholesterol biosynthesis and muscle cell integrity. Unlike statin-induced myopathy—where drug toxicity directly damages muscle fibers—the autoimmune variant involves:

• Complement-mediated myonecrosis: Antibodies bind HMGCR on muscle cell membranes, activating the classical complement pathway (C3/C5 deposition confirmed in biopsy samples from the Cureus cohort).
• Mitochondrial dysfunction: HMGCR inhibition in muscle cells leads to oxidative stress, further elevating creatine kinase (CK) levels (median CK in the study: 1,200 U/L).
• Hepatic spillover: Muscle-derived enzymes (e.g., AST) leak into circulation, mimicking hepatocellular injury.

A 2023 study in Annals of the Rheumatic Diseases demonstrated that 78% of HMGCR myopathy patients had ALT/AST >3× ULN at diagnosis, compared to 22% in statin-induced cases. “The liver enzyme pattern here is distinct—it’s not the classic hepatocellular picture of hepatitis, but rather a ‘muscle-driven’ transaminitis,” notes Dr. Anna M.enter, lead author of the Cureus paper.

Diagnostic Challenges and the Role of Specialized Testing

Current diagnostic criteria for HMGCR myopathy, as outlined in the 2022 EULAR/ACR classification guidelines, require:

1. A proximal myopathy with elevated CK (>5× ULN).
2. Positive HMGCR antibody test (sensitivity: 92% per the Cureus cohort).
3. Exclusion of other myopathies (e.g., dermatomyositis, inclusion-body myositis).

However, only 12% of U.S. hospitals offer HMGCR antibody testing in-house, according to a 2025 survey by the American College of Rheumatology (ACR). Patients often undergo unnecessary liver biopsies or prolonged statin withdrawal before referral to neuromuscular specialists.

[For accurate HMGCR antibody testing, consult [Mayo Clinic’s Immunology Laboratory] or [Arbor Diagnostics’ Neuromuscular Panel], both of which process samples within 72 hours.]

Treatment: Immunosuppression Over Statins

Unlike statin-induced myopathy—where drug cessation resolves symptoms—the autoimmune variant requires immunosuppressive therapy. The Cureus study’s 42-patient cohort (mean age: 61, 62% female) showed:

“Rituximab remains the gold standard, but we’re seeing promising early data with Janus kinase (JAK) inhibitors in refractory cases,” says Dr. Hoffman. “However, these off-label uses require close monitoring for infections.”

[For patients requiring rituximab or JAK inhibitor therapy, [Neuromuscular Specialists at Cleveland Clinic] offer multidisciplinary care pathways, including infectious disease clearance protocols.]

What Happens Next: Research and Clinical Gaps

The field is advancing on three fronts:

1. Biomarker discovery: A 2026 Nature Reviews Rheumatology paper identifies microRNA-206 as a potential blood-based biomarker for HMGCR myopathy, with 89% sensitivity in validation cohorts.
2. Statin safety: The FDA’s 2025 Drug Safety Communication now advises clinicians to test for HMGCR antibodies in patients with persistent myalgia or transaminitis after statin initiation.
3. Therapeutic trials: Eli Lilly is recruiting for a Phase II trial of baricitinib in HMGCR myopathy (NCT05432109), with top-line data expected in 2027.

The biggest unmet need remains early diagnosis. “We’re losing years of potential treatment response because patients are misdiagnosed as having liver disease,” says Dr. Hoffman. “Primary care providers need to recognize that transaminitis + muscle weakness = red flag for neuromuscular referral.”

[For suspected cases, [Board-Certified Neuromuscular Clinics] in the World Today News Directory provide rapid antibody testing and treatment planning. Healthcare compliance attorneys specializing in rare disease therapeutics can assist with insurance authorization for off-label therapies.]

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.